How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pneumonia-due-to-mycoplasma-pneumoniae.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pneumonia due to Mycoplasma pneumoniae — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pneumonia due to Mycoplasma pneumoniae (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumonia due to Mycoplasma pneumoniae, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xenleta	LEFAMULIN	Hong Kong	Pleuromutilin Antibacterial		2019-01-01
Ketek	TELITHROMYCIN	Sanofi	Ketolide Antibacterial	Potassium voltage-gated channel subfamily H member 2	2004-01-01
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Tomefloxacin	GREPAFLOXACIN	Otsuka	grepafloxacin	Potassium voltage-gated channel subfamily H member 2	1997-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Pneumonia due to Mycoplasma pneumoniae
Pfizer · 2 drugs in Pneumonia due to Mycoplasma pneumoniae
Lg Chem Ltd · 2 drugs in Pneumonia due to Mycoplasma pneumoniae
Bayer AG · 1 drug in Pneumonia due to Mycoplasma pneumoniae
Bulovka Hospital · 1 drug in Pneumonia due to Mycoplasma pneumoniae
Generic (originally Abbott/AbbVie) · 1 drug in Pneumonia due to Mycoplasma pneumoniae
Generic (originally Abbott/Lilly) · 1 drug in Pneumonia due to Mycoplasma pneumoniae
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Pneumonia due to Mycoplasma pneumoniae
Generic (originally Pfizer) · 1 drug in Pneumonia due to Mycoplasma pneumoniae
Hong Kong · 1 drug in Pneumonia due to Mycoplasma pneumoniae
Novartis Pharmaceuticals · 1 drug in Pneumonia due to Mycoplasma pneumoniae
Otsuka · 1 drug in Pneumonia due to Mycoplasma pneumoniae

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumonia due to Mycoplasma pneumoniae:

Cite this brief

Drug Landscape (2026). Pneumonia due to Mycoplasma pneumoniae — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumonia-due-to-mycoplasma-pneumoniae. Accessed 2026-06-10.

Pneumonia due to Mycoplasma pneumoniae full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing